TheraVet: BIOCERA-VET Nominated for the Veterinary Innovation Award (AFVAC 2022)

Posted on December 12, 2022 by Design in Design Innovation | 0 Comments

Regulatory News:

TheraVet (ISIN code: BE0974387194 mnemonic: ALVET), a pioneering biotechnology company in the treatment of bone and joint diseases in pets, today announces that BIOCERA-VET, its injectable bone cement, was nominated for the Veterinary Innovation Award (AFVAC, Marseille, France) and that, pursuing its commercial strategy, its management team participated in the following events:

This year, the AFVAC also organized the fifth edition of the Veterinary Innovation Awards, with the aim of honoring innovative companies in the field of health and well-being of companion animals and promoting these initiatives with practitioners. BIOCERA-VET, TheraVet’s injectable bone cement, was one of the three nominated by a jury made up of personalities from the veterinary world for the Veterinary Innovation Prize in the Equipment and Devices category.

About TheraVet

TheraVet is a veterinary biotechnology company specializing in bone and joint treatments in animal health. The Company develops targeted, safe and effective treatments to improve the quality of life of companion animals suffering from joint and bone diseases. The health of pets is at the heart of their owners’ concerns and TheraVet’s mission is to meet the need for innovative and curative treatments. TheraVet works closely with international thought leaders to better meet the ever-growing needs of veterinary medicine. TheraVet is listed on Euronext Growth Paris and Brussels, its head office is located in Gosselies, Belgium, and the Company has a US subsidiary.

For more information, visit our websiteor follow us on LinkedInFacebookTwitter

About BIOCERA-VETBIOCERA-VET is a complete range of innovative, easy-to-use, effective and cost-effective bone substitutes indicated in bone surgeries requiring bone grafting as well as in the palliative management of canine osteosarcoma. Based on extremely promising clinical results, this product line allows an evolution towards simpler and more efficient orthopedic surgery.

BIOCERA-VET is available in several lines:

For more information, visit our site BIOCERA-VET

View source version on businesswire.com: https://www.businesswire.com/news/home/20221206005922/en/

Contacts:

TheraVet
Chief Operating Officer

Sabrina Ena

[email protected]
+32 (0) 71 96 00 43

Chief Corporate Officer

Julie Winand

[email protected]

NewCap
Relations Investisseurs Communication Financière

Théo Martin Nicolas Fossiez

[email protected]
+33 (0) 1 44 71 94 94

Relations Presse

Arthur Rouillé

[email protected]
+33 (0) 1 44 71 00 15

NewCap Belgique
Relations Presse

Laure-Eve Monfort

[email protected]
+32 (0) 489 57 76 52